Tyan K - Search Results

1

Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes.

Tyan K, Bae JE, Lorch JH, Margalit DN, Tishler RB, Huynh MA, Jo VY, Haddad RI, Chau NG, Hanna GJ, Schoenfeld JD. Tyan K, et al. Head Neck. 2022 Mar;44(3):722-734. doi: 10.1002/hed.26964. Epub 2021 Dec 19. Head Neck. 2022. PMID: 34927307

2

[No title available]

[No authors listed] [No authors listed] PMID: 34701400

3

Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy.

Liu KX, Sierra-Davidson K, Tyan K, Orlina LT, Marcoux JP, Kann BH, Kozono DE, Mak RH, White A, Singer L. Liu KX, et al. Among authors: tyan k. Radiother Oncol. 2021 Dec;165:44-51. doi: 10.1016/j.radonc.2021.10.012. Epub 2021 Oct 22. Radiother Oncol. 2021. PMID: 34695520 Free PMC article.

4

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.

Rahma OE, Tyan K, Giobbie-Hurder A, Brohl AS, Bedard PL, Renouf DJ, Sharon E, Streicher H, Hathaway E, Cunningham R, Manos M, Severgnini M, Rodig S, Stephen Hodi F. Rahma OE, et al. Among authors: tyan k. J Immunother Cancer. 2022 Mar;10(3):e003569. doi: 10.1136/jitc-2021-003569. J Immunother Cancer. 2022. PMID: 35264434 Free PMC article. Clinical Trial.

5

[No title available]

[No authors listed] [No authors listed] PMID: 34701470

6

Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.

Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Grover S, et al. Among authors: tyan k. Cancer. 2020 Aug 15;126(16):3758-3767. doi: 10.1002/cncr.32966. Epub 2020 Jun 22. Cancer. 2020. PMID: 32567084 Free PMC article.

7

Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.

Tyan K, Baginska J, Brainard M, Giobbie-Hurder A, Severgnini M, Manos M, Haq R, Buchbinder EI, Ott PA, Hodi FS, Rahma OE. Tyan K, et al. Cancer Immunol Immunother. 2021 Aug;70(8):2209-2221. doi: 10.1007/s00262-021-02855-1. Epub 2021 Jan 22. Cancer Immunol Immunother. 2021. PMID: 33481042 Free PMC article.

8

Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling.

Tyan K, Abu-Shawer O, Baginska J, Severgnini M, Manos M, Vaitkevicius H, Grover S, Hodi FS, Rahma OE. Tyan K, et al. Immunotherapy. 2022 Aug;14(11):843-850. doi: 10.2217/imt-2021-0298. Epub 2022 Jun 13. Immunotherapy. 2022. PMID: 35695027

9

Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.

Bui AN, Tyan K, Giobbie-Hurder A, Klein IA, Manos MP, Zubiri L, Reynolds K, Grover S, Weinhouse GL, Ott PA, LeBoeuf NR, Rahma O. Bui AN, et al. Among authors: tyan k. J Immunother Precis Oncol. 2021 May 14;4(2):35-44. doi: 10.36401/JIPO-20-34. eCollection 2021 May. J Immunother Precis Oncol. 2021. PMID: 35663537 Free PMC article.

10

Considerations for the Selection and Use of Disinfectants Against SARS-CoV-2 in a Health Care Setting.

Tyan K, Levin A, Avalos-Pacheco A, Plana D, Rand EA, Yang H, Maliszewski LE, Chylek LA, Atta L, Tye MA, Carmack MM, Oglesby NS, Burgin S, Yu SH, LeBoeuf NR, Kemp JM. Tyan K, et al. Open Forum Infect Dis. 2020 Aug 31;7(9):ofaa396. doi: 10.1093/ofid/ofaa396. eCollection 2020 Sep. Open Forum Infect Dis. 2020. PMID: 32989420 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters